A few thoughts have been rattling around in my head recently.
This issue’s cover story on AI in microbiology in conjunction with this issue being the first one of 2026, and the publishing industry’s penchant for printing yearly forecast stories this time of year got me thinking we should combine them.
Let’s get really “meta” and ask AI to forecast how AI will impact the pharmaceutical industry in 2026.
Sounds fun, doesn’t it? I frequently use Perplexity AI for research purposes, so here it what it came up with:
AI will shift from pilots to core infrastructure in pharma by 2026, especially in discovery, trials, manufacturing, and commercial execution.
Generative AI in drug discovery
- Models design novel molecules, optimize properties in silico, and prioritize candidates before lab work, integrating omics and structural data.
- By 2026, GenAI becomes standard in hit identification and lead optimization, with clear examples of faster IND timelines and more pharma–AI biotech partnerships.
- Generative AI in drug discovery is projected to grow from a few hundred million dollars mid 2020s to several billion dollars by the early to mid 2030s.
AI-augmented clinical trials
- AI supports protocol design, site selection, recruitment, feasibility, and real time monitoring using historical trial and real world data.
- By 2026, AI based feasibility and recruitment analytics will be routine in many Phase II/III studies, with regulators demanding transparency for AI driven selection methods.
- The AI in clinical trials space is expected to reach the mid single to high single digit billions of dollars globally by 2030.
AI in manufacturing and supply chain
- Advanced analytics enable predictive maintenance, real time process control, and multivariate monitoring, plus smarter demand and inventory management.
- By 2026, leading pharmas and CDMOs will run AI backed continuous verification and anomaly detection across critical assets and tech transfer workflows.
- AI in biotech, including process optimization, is projected to surpass USD 10 billion by 2030, with manufacturing a key contributor.
AI for personalized and real world data medicine
- AI links genomics, imaging, EMR, and claims data to identify subpopulations, refine labels, and support companion diagnostics and treatment decisions.
- By 2026, AI driven stratification will be routine in oncology and rare diseases, influencing trial design, labels, and market access.
- Precision and real world data applications are a major driver within an AI-in-biotech market expected to exceed USD 11 billion by 2030.
Enterprise AI platforms and copilots
- Cross functional platforms and copilots assist with medical writing, regulatory dossiers, safety triage, and commercial analytics on governed internal data.
- By 2026, most top 20 pharmas will deploy enterprise AI stacks with role specific copilots across R&D, safety, regulatory, manufacturing, and commercial teams.
- The overall AI-in-pharma market is projected to reach roughly USD 15–25 billion by 2030, with platforms and software capturing a growing share.
So – what do you think?
Are AI’s predictions for 2026 possible? Completely off the mark? Is AI just hallucinating?
Let me know what you think will be AI’s impact on the industry in 2026.
I would even be open to publishing a roundtable of responses.
Right after I run it through AI.
Mike Auerbach
Pharma Group Editor-in-Chief
mauerbach@comparenetworks.com
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!